As manufacturers invest in clinical development of rare disease therapies, payers are examining disease prevalence estimates and determining reimbursements. In this article published in Life Science Leader, Cécile Matthews and Bhavesh Patel discuss factors payers are considering for such reimbursements. The authors recently conducted an analysis of 15 rare and ultra-rare disease therapies recently approved in France, Germany, Italy, Spain, the UK, and Japan to better understand the factors payers are now considering for reimbursement of rare disease drugs.
Consequences of counterfeit pharmaceutical product sales
Recently, both the FDA and EMA have raised concerns about counterfeit drug products, including GLP-1s used for weight loss and diabetes, being marketed in the...